Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 3,806Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 12Tarceva

PharmaCompass

01

Brand Name : Tarceva

Erlotinib

arrow
euroPLX 86 Munich
Not Confirmed

Brand Name : Tarceva

arrow
euroPLX 86 Munich
Not Confirmed

Erlotinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 10

2019 Revenue in Millions : 51

Growth (%) : -80

blank

02

Brand Name : Tarceva

Erlotinib

arrow
euroPLX 86 Munich
Not Confirmed

Brand Name : Tarceva

arrow
euroPLX 86 Munich
Not Confirmed

Erlotinib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 307

2018 Revenue in Millions : 554

Growth (%) : -45

blank

03

Brand Name : Tarceva

Erlotinib

arrow
euroPLX 86 Munich
Not Confirmed

Brand Name : Tarceva

arrow
euroPLX 86 Munich
Not Confirmed

Erlotinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 178

2019 Revenue in Millions : 332

Growth (%) : -46

blank

04

Brand Name : Tarceva

Erlotinib

arrow
euroPLX 86 Munich
Not Confirmed

Brand Name : Tarceva

arrow
euroPLX 86 Munich
Not Confirmed

Erlotinib

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 171

2017 Revenue in Millions : 270

Growth (%) : -37%

blank

05

Brand Name : Tarceva

Erlotinib

arrow
euroPLX 86 Munich
Not Confirmed

Brand Name : Tarceva

arrow
euroPLX 86 Munich
Not Confirmed

Erlotinib

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 331

2015 Revenue in Millions : 443

Growth (%) : -25

blank

06

Brand Name : Tarceva

Erlotinib

arrow
euroPLX 86 Munich
Not Confirmed

Brand Name : Tarceva

arrow
euroPLX 86 Munich
Not Confirmed

Erlotinib

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 288

2016 Revenue in Millions : 353

Growth (%) : -18

blank

07

Brand Name : Tarceva

Erlotinib

arrow
euroPLX 86 Munich
Not Confirmed

Brand Name : Tarceva

arrow
euroPLX 86 Munich
Not Confirmed

Erlotinib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 51

2018 Revenue in Millions : 563

Growth (%) : -91

blank

08

Brand Name : Tarceva

Erlotinib

arrow
euroPLX 86 Munich
Not Confirmed

Brand Name : Tarceva

arrow
euroPLX 86 Munich
Not Confirmed

Erlotinib

Main Therapeutic Indication : Oncology

Currency : USD

2014 Revenue in Millions : -3.50%

2013 Revenue in Millions :

Growth (%) :

blank

09

Brand Name : Tarceva

Erlotinib

arrow
euroPLX 86 Munich
Not Confirmed

Brand Name : Tarceva

arrow
euroPLX 86 Munich
Not Confirmed

Erlotinib

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 1,305

2014 Revenue in Millions : 1,193

Growth (%) : -9%

blank

10

Brand Name : Tarceva

Erlotinib

arrow
euroPLX 86 Munich
Not Confirmed

Brand Name : Tarceva

arrow
euroPLX 86 Munich
Not Confirmed

Erlotinib

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 1,014

2015 Revenue in Millions : 1,169

Growth (%) : -13

blank